Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
10:56am, Thursday, 14'th Mar 2024
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
06:31pm, Monday, 11'th Mar 2024
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:15pm, Monday, 11'th Mar 2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
09:15am, Thursday, 29'th Feb 2024
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Wednesday, 28'th Feb 2024
AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
06:56am, Monday, 19'th Feb 2024
AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference
09:15am, Wednesday, 31'st Jan 2024
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?
11:17am, Thursday, 07'th Dec 2023
The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclus
Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround
11:18am, Tuesday, 14'th Nov 2023
AnaptysBio, Inc. (ANAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Anaptys Announces Participation in November Investor Conferences
09:15am, Wednesday, 01'st Nov 2023
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
09:15am, Wednesday, 11'th Oct 2023
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcom
AnaptysBio's skin disease drug meets main goal in late-stage study
08:32am, Monday, 09'th Oct 2023
AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
09:15am, Tuesday, 12'th Sep 2023
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan
AnaptysBio: Despite Early Successes, Current Situation Does Not Impress
10:33am, Friday, 07'th Jul 2023
AnaptysBio, Inc. had major deals with big pharma in past years. However, its current programs are not that convincing. They have a lot of cash from earlier deals.
